I thought so too. But they did offer me a free glass of wine with some pharma delegates, and a free registration to the conference. But I think I would prefer to stab my eyeballs with toothpicks. 

________________________________

From: Richard Ashcroft [mailto:[log in to unmask]]
Sent: Mon 2/16/2009 8:46 PM
To: Oliver,AJ
Cc: [log in to unmask]
Subject: Re: Question



considering what they charge to delegates, they are extracting the 
urine in not offering a speaker fee.  they work on a commercial basis; 
so should we.

Quoting Adam Oliver <[log in to unmask]>:

> Does anyone else get these messages from this company? They asked me 
>  to give a presentation for them, and when I asked about a stipend,  
> they said they don't pay speakers because it would undermine the  
> integrity of their conferences (or something like that). If they ask 
>  me again, I'll say that I'll do it for free so long as they donate  
> the profits they make from their conferences and reports to charity.
>
>
>
> We have to make some kind of stand at some point. We'll all be dust  
> in 80 years.
>
>
>
>
>
>
>
> ________________________________
>
> From: Nini Wei --- Visiongain [mailto:[log in to unmask]]
> Sent: 16 February 2009 12:44
> To: Oliver,AJ
> Subject: Therapeutic Monoclonal Antibodies Report 2008-2023
>
>
>
>
>
> Therapeutic Monoclonal Antibodies Report 2008-2023
>
>
>
>
>
>
>
> *  Publication date: 25/07/2008
>
> *  Number of Pages: 141
>
> ________________________________
>
>
> *  Report Details
>
>
> This brand new report investigates the global market for therapeutic 
>  monoclonal antibodies. While the pharmaceutical industry as a whole 
>  is suffering from single digit growth, thinner pipelines than 
> before  and pressure from an ever-aggressive generics industry, the 
> segment  of monoclonal antibodies therapeutics is thriving and 
> growing at a  double-digit rate. Therapeutic Monoclonal Antibodies 
> 2008-2023 shows  how monoclonal antibodies are a leading product of 
> biotechnology,  being increasingly used in therapy. Currently, 
> monoclonal antibodies  are playing an important role in the 
> treatment of cancer, autoimmune  and inflammatory disorders. 
> Therapeutic monoclonal antibodies boast  one of the most active and 
> promising pipelines in the pharmaceutical  industry.
>
> Ten years ago, there were only two monoclonal antibody drugs on the  
> world market, now there are 21 FDA approved therapies - including  
> eight blockbuster drugs. In 2007, the market was worth $21.9bn, but  
> what will it be in 5 years time? This report will tell you and tell  
> you today. Visiongain believes that some of the greatest  
> opportunities ever available for biopharmaceutical companies are now 
>  there to be seized, with important sales, licensing agreements and  
> collaborative partnerships from the present onwards in monoclonal  
> antibodies and other biologicals.
>
> Our new Therapeutic Monoclonal Antibodies 2008-2023 report examines  
> the market for monoclonal antibodies critically, through  
> comprehensive primary and secondary research. In addition to  
> consultation with experts in industry - including full interview  
> transcripts - this research involved a detailed study of relevant  
> documents, industrial reports and current developments. Visiongain  
> discusses the monoclonal antibody market in the context of the  
> biotechnological platforms and therapeutic areas.  Importantly,  
> visiongain applied techniques such as financial forecasting and  
> analysis of drivers and restraints. The result is a comprehensive  
> market-based report with detailed analyses and informed opinion.
>
> In particular, Therapeutic Monoclonal Antibodies 2008-2023  
> concentrates on the following essential aspects of the monoclonal  
> antibodies sector:
> * Technologies that drive the MAb sector
> * Therapy areas that drive the MAb sector
> * Sales forecasts of the global therapeutic MAb market from  
> 2008-2023 - including those of principal market segments, both by  
> disease area and technology
> * Sales forecasts for leading products worldwide in this sector
> * Sales forecasts for therapeutic MAb sales in leading national  
> markets, including China and India
> * Key industrial players in the therapeutic monoclonal antibody  
> sector - both established and emerging - including partnerships
> * Drivers and opportunities in the MAb sector
> * Restraints and threats in the MAb sector
> * Assessments of relevant business models, technological solutions  
> and associated issues
> * Coverage of future trends in MAbs, especially pipeline developments
> * Insight from interviews with relevant experts
>
> Why you should buy this report:
> * To receive a comprehensive analysis of the prospects for the  
> therapeutic monoclonal antibodies industry from 2008-2023, including 
>  sales forecasts, major growth areas and pipeline products
> * To discover predicted revenues, growth rates and other key metrics 
>  in the therapeutic monoclonal antibodies market from 2008-2023,  
> especially for leading brands
> * To determine the forces that influence the therapeutic monoclonal  
> antibodies market:
> * Drivers and restraints on market
> * Competition
> * Strengths, weaknesses, opportunities and threats.
> * To find out where the therapeutic monoclonal antibodies market is  
> heading from 2008 onwards - both technologically and commercially
>
> ________________________________
>
>
> Pricing
>
> - Individual report pricing - single user copies of this report are  
> available for only GBP£1499
> - Departmental copies (this entitles up to 5 individual users in  
> your department) of this report are available for only GBP£2999 .  
> This is not suitable for library usage.
> - Allow your whole company to have access to this information for  
> only GBP£4999 . Company-wide License allows your whole company  
> access and intranet use on CD Rom and .pdf. Suitable for library  
> storage and use.
> - Does your company have over 2,500 employees? Have the whole  
> company access this information for a special rate of only GBP£6999
>
>
> Ordering
>
> Ordering is simple! All you need to do to order this report is  
> contact Nini . You can either call me on TEL: +44 (0)207 549 9971 or 
>  email maito: <mailto:> [log in to unmask]  
> <mailto:[log in to unmask]>
>
> *  Please feel free to contact me should you have any questions, or  
> wish to purchase a copy, I look forward to hearing from you.
>
> King Regards
>
> Nini Wei
> Visiongain Ltd.
> BSG House,
> 226-236 City Road
> London EC1V 2QY
> Tel:  +44 (0) 20 7549 9971
> Fax:  +44 (0) 20 7549 9930
>
> ________________________________
>
>
> Table of Contents
>
> 1 Executive Summary
> 1.1 Aims of This Report
> 1.2 A Brief Overview of the Chapters
>
> 2 Introduction
> 2.1 What is a Monoclonal Antibody?
> 2.1.1 Structure of Antibodies
> 2.1.2 Function of Antibodies
> 2.2 History of Therapeutic Monoclonal Antibody Development
> 2.2.1 Different Types of Therapeutic Antibody
> 2.2.2 Timeline for Monoclonal Antibodies in Therapy
> 2.3 There are 21 FDA Approved Therapeutic Monoclonals
> 2.4 Monoclonal Antibodies are a Thriving Part of the Biotech Market
> 2.4.1 MAbs Lead the Market
> 2.5 The Monoclonal Antibody Market is Taking Off
>
> 3 World Market for Therapeutic Monoclonal Antibodies
> 3.1 Summary of Key Findings
> 3.2 Therapeutic Monoclonal Antibodies Generated Over $21bn in 2007
> 3.3 World Therapeutic Monoclonal Antibodies Market Forecast 2008-2023
> 3.4 Market Analysis of the Leading Products - the 'Big 5'
> 3.4.1 Remicade is Leading the Pack, but Will it Last?
> 3.5 Market Forecast by Therapeutic Analysis
> 3.5.1 Oncology Drugs Dominate in the Monoclonal Antibody Market
> 3.5.1.1 Over Half of Monoclonal Antibody Revenues are from Oncology Products
> 3.5.1.2 Cancer Drugs will Drive the Market
> 3.5.2 AIID is Second in Line
> 3.5.2.1 AIID Narrows the Gap
> 3.5.3 Other Therapeutic Areas are also Growing Quickly
> 3.5.3.1 Other Therapeutic Areas Represent 10% of the Market
> 3.6 Market Forecast by Technology Analysis
> 3.6.1 Chimeric Antibodies Retiring from the Spotlight
> 3.6.2 Humanised Antibodies Moving to Centre Stage
> 3.6.3 Fully Human Antibodies Set to Become the Next Star
> 3.6.4 A Change of Guard in Technology Forerunners
>
> 4 Forces Affecting the Therapeutic Monoclonal Antibodies Market
> 4.1 SWOT Analysis of the Therapeutic Monoclonal  Antibodies Market
> 4.2 Monoclonal Drugs Constitute a Thriving Market
> 4.2.1 Monoclonal Technology Allows a Wide Range of Targets
> 4.2.2 Cancer Drugs Lead the Monoclonal Market
> 4.2.3 Chronic and Niche Diseases Generate High Revenues
> 4.2.4 There is a Lower Risk of Adverse Events for Monoclonals
> 4.2.5 Monoclonal Antibodies Avoid Biogeneric Competition
> 4.2.6 Rising Expenditures of Prescription Drugs Stimulate Market Growth
> 4.3 Pipeline Developments in Monoclonal Antibody Therapies are Very Promising
> 4.3.1 New Production Methods Will Reduce Costs
> 4.3.2 Flexible Formats to Fill Unmet Needs in Oncology
> 4.3.3 Innovative Combination Uses of Existing Products
> 4.4 Weaknesses and Threats Will Hold Back the Monoclonal Market to  
> Some Degree
> 4.4.1 Big and Expensive: Developmental Costs Limit Growth
> 4.4.2 Injections are the Main Mode of Administration
> 4.4.3 The Challenge of Immunogenicity Looms Large
> 4.4.4 High Profile Safety Cases Increase Regulatory Concerns
> 4.4.5 Competition is Fierce for Many Prime Targets
>
> 5 Leading Marketed and Pipeline Products for Therapeutic Monoclonal  
> Antibodies
> 5.1 The 'Big 5' Will Continue to Dominate the Market
> 5.1.1 Remicade (Johnson and Johnson)
> 5.1.1.1 Doubts Linger Around Remicade
> 5.1.2 Rituxan/MabThera (Roche/Genentech)
> 5.1.2.1 Rituxan Grows to $6.4bn by 2013
> 5.1.3 Herceptin (Roche/Genentech)
> 5.1.3.1 Herceptin Faces Tough Competition
> 5.1.4 Avastin (Roche/Genentech)
> 5.1.4.1 Avastin to Drive the Growth and Innovation of Therapeutic Antibodies
> 5.1.5 Humira (Abbott)
> 5.1.5.1 Humira Has Immense Opportunities
> 5.2 Market Analysis of the Emerging Products - The Three Other Blockbusters
> 5.2.1 Erbitux (Merck/ImClone)
> 5.2.1.1 Erbitux Does Not Have Enough to Overtake Avastin
> 5.2.2 Lucentis (Roche/Genentech)
> 5.2.2.1 Growth Flattens for Lucentis
> 5.2.3 Synagis (AstraZeneca)
> 5.2.3.1 Pessimism Surrounds Synagis
> 5.3 Top Seven Products to Watch
> 5.3.1 Cimzia (UCB)
> 5.3.2 Golimumab (Johnson and Johnson)
> 5.3.3 Denosumab (Amgen)
> 5.3.4 Numax (AstraZeneca/MedImmune/Applied Molecular Evolution)
> 5.3.5 Bapineuzumab (Elan/Wyeth)
> 5.3.6 ABT-874 (Abbott)
> 5.3.7 Ustekinumab (Johnson and Johnson)
>
> 6 Therapeutic Monoclonal Antibodies Market Dynamics
> 6.1 Therapeutic Monoclonal Antibodies Market Finds Success Outside  
> of the Traditional
>       Blockbuster Model
> 6.2 Therapeutic Monoclonal Antibodies - a High-Value Market with a  
> High Barrier of
>       Entry
> 6.3 Big Pharma is Moving into the Market
> 6.4 Strategic Alliances Help to Accelerate Market Growth
> 6.5 Roche and Genentech's Partnership Follows a Winning Business Blueprint
> 6.6 A Market Monopolised by Three Giants
> 6.6.1 Roche/Genentech Has Absolute Control in the Market
> 6.6.1.1 Marketed Monoclonal Antibody Therapies
> 6.6.1.2 Pipeline Analysis
> 6.6.1.3 Strategic Analysis
> 6.6.2 Johnson and Johnson Looking to Secure Leadership in Autoimmune 
>  Antibodies
> 6.6.2.1 Marketed Monoclonal Antibody Therapies
> 6.6.2.2 Pipeline Analysis
> 6.6.2.3 Strategic Analysis
> 6.6.3 Abbott Ties its Future to Humira
> 6.6.3.1 Marketed Monoclonal Antibody Therapies
> 6.6.3.2 Pipeline Analysis
> 6.6.3.3 Strategic Analysis
> 6.7 Emerging Player to Watch
> 6.7.1 Amgen Bets on Bone Diseases
> 6.7.1.1 Marketed Monoclonal Antibodies Therapies
> 6.7.1.2 Pipeline Analysis
> 6.7.1.3 Strategic Analysis
>
> 7 Therapeutic Monoclonal Antibodies in the Leading Pharmaceutical Markets
> 7.1 Sales of Therapeutic Monoclonal Antibodies in the US
> 7.1.1 Increasing Prevalence of Cancer Will Drive Sales in the US Market
> 7.1.2 High Economic Cost of Cancer and Autoimmune Diseases Will  
> Drive Sales of
>          Monoclonal Antibodies
> 7.2 The European Market for Monoclonal Antibodies Will Increase Moderately
> 7.3 Developing Countries are Thriving
> 7.4 China and India Rise Up
>
> 8 Interviews with Industry Experts: Therapeutic Monoclonal  
> Antibodies - Current and Future Trends
> 8.1 Interview 1: Professor Joe Cummins, Professor Emeritus of  
> Genetics, University of
>       Western Ontario, Canada.
> 8.1.1 Safety Concerns for Therapeutic Monoclonal Antibodies
> 8.1.2 Excitement Surrounding Therapeutic Monoclonal Antibodies
> 8.1.3 Prospects of Fully Human Antibodies
> 8.1.4 Prospects of the Therapeutic Monoclonal Antibodies Market
> 8.2 Interview 2: Dr Martin Wiles, Vice President of Business Development,
>       BioInvent, Sweden
> 8.2.1 Greatest Obstacles to Market Growth
> 8.2.2 Prospects of Fully Human Antibodies
> 8.2.3 Prospects of Therapeutic Monoclonal Antibodies Market
> 8.2.4 Most Promising Products
> 8.2.5 Long-Term Collaborative Partnership between BioInvent and ThromboGenics
>
> 9 Future Trends for Therapeutic Monoclonal Antibodies
> 9.1 Are Magic Bullets Back in Vogue?
> 9.1.1 Immunogen's TAP System Attracts Attention
> 9.1.2 Seattle Genetics ADC Technology Shows Promise
> 9.2 Nanobodies, BiTEs and TandAbs - New Takes on the Monoclonal
> 9.2.1 BiTEs Can Thwart CD8 Negative Tumours
> 9.2.2 TandAbs Specialise in Tumour Killing
> 9.2.3 NanoBodies - Heavy Chain Only Technology
> 9.3 Diagnostic Tests Will Be Integral to Future Success
> 9.3.1 Lack of Low Hanging Fruit Will Force Integration
>
> 10 Conclusion: the Monoclonal Antibodies Market is Growing Strongly and Will
>      Become a Leading Therapeutic Technology
> 10.1 The Monoclonal Antibodies Market is One of the Strongest Areas in the
>         Pharmaceutical Industry
> 10.2 Oncology is the Key Driver to Market Growth
> 10.3 Humanised Monoclonal Antibodies Will Dominate the Market in the 
>  Short-Term,
>         but Fully Human Antibodies are the Focal Point of Research Interest
> 10.4 Monoclonal Antibody Therapies Will Reach More Countries
> 10.5 The Market Will Be Restrained by Competition and Price Restrictions
> 10.6 Monoclonal Antibodies Will Become the Mainstream Therapeutic  
> Technology in
>         the Industry
> 10.7 Outlook for the Future
>
> List of Tables
> Table 2.1 FDA-Approved Therapeutic Monoclonal Antibodies, 2008
> Table 2.2 Leading Biotech Drugs Based on Monoclonal Antibodies, 2007
> Table 3.1 Leading Therapeutic Monoclonal Antibodies, Sales ($m) and  
> Market Share (%), 2007
> Table 3.2 Global Sales ($bn) by Therapeutic Area, 2007
> Table 3.3 Statistics of Key Oncology Indications and Their  
> Monoclonal Antibody Therapies, 2007
> Table 3.4 Prevalence of Key AIID Indications and Their Monoclonal  
> Antibody Therapies, 2007
> Table 4.1 SWOT Analysis of the Monoclonal Antibody Market, 2008
> Table 4.2 Targets and Indications for Selected Approved Antibodies
> Table 4.3 Modes of Administration for Leading Monoclonal Antibody Drugs
> Table 5.1 Global Market for the Emerging Three, Sales ($bn) and  
> Market Share (%), 2007-2013
> Table 6.1 Key Mergers and Acquisitions of the Monoclonal Antibody Market
> Table 6.2 Near-Term Opportunities in the Roche Group's Pipeline, 2008
> Table 6.3 Near-Term Opportunities in Johnson and Johnson's Pipeline, 2008
> Table 6.4 Near-Term Opportunities in Abbott's Pipeline, 2008
> Table 6.5 Near-Term Opportunities in Amgen's Pipeline, 2008
> Table 7.1 Leading Regions of the Therapeutic Monoclonal Antibodies  
> Market, Sales ($m) and Market Share (%), 2007 and 2013
> Table 9.1 Examples of Conjugated Monoclonal Drugs in the Pipeline, 2008
> Table 9.2 Immunogen's Product Pipeline, 2008
> Table 9.3 Other Monoclonal-based Drugs in Development Using the TAP  
> System, 2008
> Table 9.4 Seattle Genetics Pipeline, 2008
> Table 10.1 Global Monoclonal Antibodies, Sales ($bn) and  Growth  
> (%), 2007-2013
> Table 10.2 Global Monoclonal Antibodies Market, Key Therapy Areas,  
> Sales ($bn) and CAGR (%), 2007-2013
> Table 10.3 Leading Geographical Markets for Monoclonal  Antibodies,  
> 2007, 2013, 2018, and 2023
>
> List of Figures
> Figure 2.1 Structure of an Antibody
> Figure 3.1 Leading Therapeutic Monoclonal Antibodies, Sales ($m), 2007
> Figure 3.2 Leading Therapeutic Monoclonal Antibodies, Market Share (%), 2007
> Figure 3.3 Leading Monoclonal Therapeutic Antibodies, Sales Growth (%), 2007
> Figure 3.4 World Therapeutic Monoclonal Antibodies, Sales ($bn), 2007-2013
> Figure 3.5 Global Therapeutic Monoclonal Antibodies, Sales Growth  
> (%), 2008-2013
> Figure 3.6 Leading Therapeutic Monoclonal Antibodies, Market Share  
> (%), 2007 and 2013
> Figure 3.7 Leading Monoclonal Antibody Therapies, Sales ($m), 2007-2013
> Figure 3.8 Global Monoclonal Antibodies Market by Therapeutic Area,  
> Sales ($bn), 2007
> Figure 3.9 Global Monoclonal Antibodies Market by Therapeutic Area,  
> Market Share (%), 2007
> Figure 3.10 Global Monoclonal Antibodies Market by Therapeutic Area, 
>  Sales ($bn), 2007-2013
> Figure 3.11 Leading Monoclonal Antibody Therapies for Oncology,  
> Sales ($m), 2007
> Figure 3.12 The Oncology Sector of Monoclonal Antibodies Market,  
> Sales ($bn), 2007-2023
> Figure 3.13 Leading Monoclonal Antibody Therapies for AIID, Sales ($m), 2007
> Figure 3.14 The AIID Sector of Monoclonal Antibodies Market, Sales  
> ($bn), 2007-2023
> Figure 3.15 Other Leading Monoclonal Antibody Therapies, Sales ($m), 2007
> Figure 3.16 Other Therapeutic Areas of Monoclonal Antibodies Market, 
>  Sales ($bn), 2007-2023
> Figure 3.17 Global Monoclonal Antibodies Market by Technology, Sales 
>  ($bn), 2007
> Figure 3.18 Global Monoclonal Antibodies Market by Technology,  
> Market Share (%), 2007
> Figure 3.19 Global Chimeric Monoclonal Antibodies Market, Market  
> Share (%), 2007
> Figure 3.20 Global Chimeric Monoclonal Antibodies Market, Sales  
> ($bn), 2007-2023
> Figure 3.21 Global Humanised Monoclonal Antibodies, Market Share (%), 2007
> Figure 3.22 Global Humanised Monoclonal Antibodies, Sales ($bn), 2007-2023
> Figure 3.23 Global Fully Human Monoclonal Antibodies Market, Market  
> Share (%), 2007
> Figure 3.24 Global Fully Human Monoclonal Antibodies Market, Sales  
> ($bn), 2007-2023
> Figure 3.25 Global Therapeutic Monoclonal Antibodies by Technology,  
> Sales ($bn), 2007-2023
> Figure 5.1 Sales of Global Monoclonal Antibodies and the Big Five  
> ($bn), 2007-2013
> Figure 5.2 Global Market Forecast for Remicade, Sales ($m), 2007-2023
> Figure 5.3 Global Market Forecast for Rituxan/MabThera, Sales ($m), 2007-2023
> Figure 5.4 Global Market Forecast for Herceptin, Sales ($m), 2007-2023
> Figure 5.5 Global Market Forecast for Avastin, Sales ($m),  2007-2023
> Figure 5.6 Global Market Forecast for Humira, Sales ($m),  2007-2023
> Figure 5.7 Global Market Forecast for Erbitux, Sales ($m),  2007-2023
> Figure 5.8 Global Market Forecast for Lucentis, Sales ($m), 2007-2023
> Figure 5.9 Global Market Forecast for Synagis, Sales ($m), 2007-2023
> Figure 6.1 Leading Companies, Total Market Share  in the World  
> Monoclonal Antibodies Market (%), 2007
> Figure 6.2 Leading Companies, Total Sales ($bn) in the World  
> Monoclonal Antibodies Market, 2007
> Figure 6.3 Roche/Genentech's Therapeutic Monoclonal Antibodies,  
> Market Share (%) and Sales ($m), 2007
> Figure 6.4 Johnson and Johnson's Marketed Portfolio, Market Share  
> (%) and Sales ($bn), 2007
> Figure 7.1 Leading Pharmaceutical Markets, Market Share (%), 2007,  
> 2013, 2018 and 2023
> Figure 7.2 Leading Pharmaceutical Markets, Sales ($m), 2007, 2013,  
> 2018 and 2023
> Figure 7.3 Leading Pharmaceutical Markets, Growth Rates (CAGR %), 2007-2013
> Figure 9.1 Antibody Formats
> Figure 10.1 Global Therapeutic Monoclonal Antibodies by Technology,  
> Sales ($bn), 2007-2023
>
> ________________________________
>
> Unsubscribe:
>
> As a valued contact or customer of Visiongain, you are receiving  
> this email with information that we believe will be relevant to you. 
>  If, however, you do not wish to receive future messages, please  
> reply to this message, typing 'unsubscribe' in the subject box of  
> your email.
>
> We support responsible and ethical email marketing practices. Please 
>  know that we respect your right to be purged from this marketing  
> campaign.
>
> Please allow 48 hours to remove your email address. Thank you for  
> your cooperation.
>
> Terms and Conditions for management reports
>
> By replying to this e-mail submitting your order for this product  
> you have agreed without limitation or qualification to be bound by  
> and to comply with these Terms and Conditions. You agree that you  
> will not fail to complete any transaction after submitting an order  
> to purchase a product or submit any order to purchase a product  
> where you do not intend to complete the transaction.
>
> Management Reports will only be sent on receipt of payment.
>
> Terms & Conditions for conferences
>
> NB - Due to high demand, we do not 'reserve' or 'hold' places - a  
> request for an invoice to be raised will be treated as an official  
> booking and will be subject to the cancellation policy as outlined  
> below. Cancellations/substitutions and name changes: All bookings  
> carry a 50% liability after the booking has been made, by post fax,  
> email or web. There will be no refunds for cancellations received on 
>  or after one month before the start of the conference (e.g.  
> cancellation on or after 20th January for a conference starting on  
> 20th February). If you decide to cancel after this date the full  
> invoice remains payable.
>
> Conference notes, which are available on the day, will be sent to you.
>
> Unfortunately we are not able to transfer places between conferences 
>  and executive briefings. However if you are unable to attend the  
> event you may make a substitution/name change at any time as long as 
>  we are informed in writing by e-mail, fax or post. Name changes and 
>  substitutions must be from the same company and are not 
> transferable  between companies or countries.
>
> Indemnity: visiongain Ltd reserve the right to change the  
> conference/executive briefing content, timing, speakers or venue  
> without notice. The event may be postponed or cancelled due to acts  
> of terrorism, war, extreme weather conditions, industrial action,  
> acts of God or any event beyond the control of visiongain Ltd. If  
> such a situation arises we will endeavour to reschedule the event.  
> However, visiongain Ltd cannot be held responsible for any cost,  
> damage or expenses, which may be incurred by the customer as a  
> consequence of the event being postponed or cancelled. We therefore  
> strongly advise all customers to take out insurance to cover the  
> cost of the registration, travel and expenses.
>
> *
>
>
>
>
>
>
> You might be interested in
>
>
> (The prices in the brochure are subject to a discount, please contact)
>
>
> ________________________________
>
>
> 1.
>
>       1.      Oncology Market Leaders - Analyses and Outlook, Market Report  
> 2008-2023 <http://www.visiongain.com/Report.aspx?rid=323>
>
>
> Oncology Market Leaders - Analyses and Outlook, Market Report 2008-2023
>
>
> The UK government have told kidney cancer patients that new drugs  
> cannot be offered on the National Health Service. Roche's Avastin,  
> Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not  
> cost-effective. The drugs -- known generically as bevacizumab,  
> sorafenib, sunitinib and temsirolimus -- should therefore not be a  
> treatment option for advanced and/or metastatic kidney cancer, NICE  
> said.
>
> ...more details <http://www.visiongain.com/Report.aspx?rid=323>
>
> ________________________________
>
>       2.      Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and  
> Dynamics - 2009-2023 <http://www.visiongain.com/Report.aspx?rid=358>
>
>
> Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics  
> - 2009-2023
>
>
> The global market for ophthalmic pharmaceuticals is a large and  
> profitable segment of the healthcare market, with ophthalmic sales  
> of over $10bn in 2007. The recent therapeutic and commercial success 
>  of Lucentis has increased the number of blockbuster ophthalmic 
> drugs  and highlighted the lucrative commercial rewards on offer in 
> this  sector. Which will be the blockbusters of the future?
>
> ...more details <http://www.visiongain.com/Report.aspx?rid=358>
>
> ________________________________
>
>       3.      World Gastrointestinal Disorders Market 2008-2023  
> <http://www.visiongain.com/Report.aspx?rid=344>
>
>
> World Gastrointestinal Disorders Market 2008-2023
>
>
> The gastrointestinal (GI) disorders market has been one of the  
> largest and most profitable therapeutic areas in the world  
> pharmaceutical industry. However. the market is now mature, with  
> well-established treatments now nearing the end of their patent  
> life. So can you and your company continue to benefit from this  
> market?
>
> ...more details <http://www.visiongain.com/Report.aspx?rid=344>
>
> ________________________________
>
>       4.      The Global Rheumatoid Arthritis Market Forecasts to 2012  
> <http://www.visiongain.com/Report.aspx?rid=238>
>
>
> The Global Rheumatoid Arthritis Market Forecasts to 2012
>
>
> In a market believed to approach 5 million people in the leading  
> pharma markets, the market for rheumatic anti-inflammatory drugs is  
> both profitable and set to increase due to new launches. The annual  
> revenue to Q3 2006, from the main prescription anti-inflammatory  
> drugs worldwide, including non steroidal anti-inflammatories  
> (NSAIDs), anti-rheumatic corticosteroid combinations and specific  
> anti-rheumatics was in the order of $16bn worldwide.
>
> ...more details <http://www.visiongain.com/Report.aspx?rid=238>
>
> ________________________________
>
>       5.      The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 
>  <http://www.visiongain.com/Report.aspx?rid=230>
>
>
> The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012
>
>
> 'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012'  
> is a new report from visiongain providing analysis of the current  
> and future market for IBD drugs across all major indications.
>
> ...more details <http://www.visiongain.com/Report.aspx?rid=230>
>
> Visiongain Upcoming Events
>
> ________________________________
>
> Japanese Pharmaceutical Market
> 26th February 2009, London, UK
>
> ________________________________
>
> Over-the-Counter 2009
> 2nd - 3rd March 2009, London, UK
>
> ________________________________
>
> 2nd Annual Biomarkers Conference
> 16th - 18th March 2009, London, UK
>
> ________________________________
>
> 5th Annual Monoclonal Antibodies
> 24th - 25th March 2009, London, UK
>
> ________________________________
>
> Pharmaceutical Packaging and Labelling Congress 2009
> 30th - 31st March 2009, London, UK
>
> ________________________________
>
> Commercial Excellence in Pharmaceuticals
> 2nd - 3rd April 2009, London, UK
>
> ________________________________
>
> Generics 2009
> 21st - 22nd April 2009, London, UK
>
> ________________________________
>
> 4th Annual Pharmacovigilance
> 22nd - 24th April 2009, London, UK
>
> ________________________________
>
> Vaccine Manufacturing
> 5th - 6th May 2009, London, UK
>
> ________________________________
>
> Patient Compliance 2009
> 18th - 19th May 2009, London, UK
>
> ________________________________
>
> Clinical Trials in Asia Summit 2009
> 18th - 20th May 2009, New Delhi, India
>
> ________________________________
>
> Health Economics and Outcomes Research 2009
> 4th - 5th June 2009, BSG House, London, UK
>
> ________________________________
>
> Clinical Trials 2009
> 8th - 9th June 2009, London, UK
>
> ________________________________
>
> 8th Annual Pricing and Reimbursement Conference
> 11th - 12th June 2009, Philadelphia, US
>
>
>
>
>
>
>
>
>
>
>
>
> Please access the attached hyperlink for an important electronic  
> communications disclaimer:  
> http://www.lse.ac.uk/collections/secretariat/legal/disclaimer.htm



--
Richard Ashcroft
Professor of Bioethics
Queen Mary, University of London
School of Law
Mile End Road
London E1 4NS
Ph: 020 7882 5126




Please access the attached hyperlink for an important electronic communications disclaimer: http://www.lse.ac.uk/collections/secretariat/legal/disclaimer.htm